Register
Login:
Share:
Email Facebook Twitter

SAR Share Chat - RSS Feed

Sareum Share Chat (SAR)



Share Price: 0.575Bid: 0.55Ask: 0.60Change: 0.00 (0.00%)No Movement on Sareum
Spread: 0.05Spread as %: 9.09%Open: 0.55High: 0.65Low: 0.55Yesterday’s Close: 0.575


Share Discussion for Sareum (SAR)


Thread ViewThread View
Please Login or Register to post messages
Posts per page:


The-Oracle
Posts: 123
Off Topic
Opinion:No Opinion
Price:0.48
It's that time again
1 May '14
"As the old blockbuster cohort declines, there is a new generation of blockbuster drugs, but many have not come from traditional large pharmaceutical companies. They are now the legacy of the big players in biotechnology like Amgen, Celgene and Gilead Sciences. The irony is that these were all small biotechnology companies not too long ago. That they are industry standard-bearers today demonstrates that mission-oriented R&D organizations driven by dynamic cultures can make scientific breakthroughs and achieve growth.

For now the stakes are high for all the players in the healthcare kingdom as an “acquire or be acquired” frenzy reigns. Once this round of mergers and acquisitions comes to an end, which invariably it must, it’s likely big pharma will return to business as usual, even though the next logical move should be to acquire larger biotechnology companies before the biotechs become the rulers of the land". Steve Brozak
 
Hopkirk
Posts: 1,139
Off Topic
Opinion:No Opinion
Price:0.48
typo
30 Apr '14
The Mayo head/neck trial linked to SAR is June 14, not September.
Hopkirk
Posts: 1,139
Off Topic
Opinion:No Opinion
Price:0.48
RE: stagnant
30 Apr '14
It's going to take news to get things moving. News of CHK1 and Aurora FLT3 clinical trials starting should be in the second half of 2014 if the current work being performed is a success. Other news (TYK2, FASN, VEGFR etc) could come at any time but the second half of this year should, IMO, see quite a bit of news come out which gets things moving. Hopefully upwards if the science is good.

Nothing much new out there at the moment but I did notice that the Mayo Clinic have updated their MV-NIS clinical trial pages here...

http://www.clinicaltrials.gov/ct2/results?term=mayo+mv-nis&Search=Search

The ovairan cancer trial has now started and the two others not directly linked to SAR have both had their expected completion dates pushed back from Nov/ Dec 13 to Sept 14. The main one which is linked to the CHK1/ ICR study on head/neck cancer still shows an expected completion date of Sept 14. If this last trial passes phase 1 it greatly derisks the whole 4-way treatment which is where the SAR / CHK1 link comes in. And if that starts and passes trials too, the value added will be well worth the wait.

But it is a good sign that the Mayo Clinc have started a new trial with MV-NIS and are continuing with the others. They should have an idea on toxicology in people by now and the fact that they have started another trial can only be seen as a good thing. Not earth shattering news for SAR today, but another of those little things like the award nomination/ Australian publication mention / Tims HMU deal talk today which all came to light recently. In isolation they don't seem too important but combined they do show things are moving in the right direction.

All IMO. GLA
BOOKMAN
Posts: 992
Off Topic
Opinion:No Opinion
Price:0.48
mmmmm
29 Apr '14
The scent of a man influences the behavior of mice and rats during experiments, increasing their stress levels and dampening their pain responses. If lab rats are scared of men but not women, that's going to skew results... and spark off some huge problems for science.

For years, anecdotal evidence has shown that lab rodents react differently to male and female experimenters. In particular, when working with men, a mouse’s pain response is dulled -- an effect called stress-induced analgesia.

“Scientists whisper to each other at conferences that their rodent research subjects appear to be aware of their presence, and that this might affect the results of experiments, but this has never been directly demonstrated until now,” Jeffrey Mogil from McGill University, Montreal, says in a news release. When scientists are unable to replicate their results, that puts their reliability to question.

Mogil and colleagues decided to look at this diminished pain response systematically. They injected the rodents’ ankles with an inflammatory agent, and then measured their pain using the “mouse grimace scale,” which examines facial expressions. The rodents showed 36 percent decrease in pain response when men, rather than women, conduct the experiment. They also exhibit increased levels of the stress hormone corticosterone, as well as body temperature.

The stress men produced in mice and rats is equivalent to restraining them for 15 minutes in a tube or forcing them to swim for three minutes. This stress-induced reaction made mice and rats of both sexes less sensitive to pain.

With further tests, they found that the “shockingly stressful” effect of male experimenters was due to smell: an olfactory stimulation from a mixture of chemicals present in human sweat. The team was able to reproduce as strong of an effect just by placing cotton T-shirts worn the night before by men next to the rodents.

The same effect was achieved when the rodents were exposed to bedding material and pet beds from other male mammals, including guinea pigs, cats, dogs, and unfamiliar rodents. But female handlers produced no such effects -- in fact, their presence (or their t-shirts) counteracted the impact of men.

That’s because the effects were caused by chemosignals, or pheromones that men secrete from their armpits at higher concentrations than women. All mammals share the same chemosignals that indicate the presence of nearby males. “It’s a primordial response,” Mogil tells Science. “If you smell a solitary male nearby, chances are he’s hunting or defending his territory.” If you’re in pain, you’re showing weakness.

This is the first evidence that an experimenter’s gender could be throwing off behavioral studies. It’s serious, but it’s not as if scientists need to redo decades of animal research. “It’s a confounding facto
Hopkirk
Posts: 1,139
Off Topic
Opinion:No Opinion
Price:0.48
Link
28 Apr '14
Hopkirk
Posts: 1,139
Off Topic
Opinion:No Opinion
Price:0.48
SAR tweet
28 Apr '14
Sareum will discuss how they made their deal with HMUBEC at UKTI's "China Life Sciences Workshop" on Weds April 30

.

Link to follow
Hopkirk
Posts: 1,139
Off Topic
Opinion:No Opinion
Price:0.48
johnnygreenfeet
28 Apr '14
I was friendly to Fork, electric (and Forks alleged husband on ADVFN) at the start.

If people ramp SAR based on facts I have no problem with it. There are lots of positive facts out there (patents which claim to inhibit tumour growth completely, studies which show tumour regression to no detectable trace, 27 fold increase in radio and chemo when used with CHK1 etc).

It was only when some facts were repeatedly intermingled with half truths and outright lies (we still don't have any of those "imminent" results, nothing has been fast tracked yet, failure is still an option) that I and others became less friendly.

I'm happy to discuss SAR with anyone but I just don't like being played.
johnygreenfeet
Posts: 1,048
Off Topic
Opinion:No Opinion
Price:0.50
friendly
28 Apr '14
unless your a piece of cutlery
Mitchellefc
Posts: 146
Off Topic
Opinion:No Opinion
Price:0.48
Hopkirk
27 Apr '14
I was in Shipley last Sunday having a beer in a new bar that's opened opposite the old bingo hall, cracking little place, can't remember what they call it though. Living in Bingley at the moment so great to just jump on train and go for a swift one or four.
Good luck with your investment.
Hopkirk
Posts: 1,139
Off Topic
Opinion:No Opinion
Price:0.48
Mitchellefc
27 Apr '14
Shipley. Moved down south 25 years ago but still go up for family, football and a decent pint when I can :)



Share Trading BrochureRequest your Free brochures on share dealing, spread betting and CFDs

Sign up for Live Prices
Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.